PCVX Vaxcyte, Inc.
QT77Latest market price
62.03
-0.58-0.93%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -7.64 | Insider Own | 0.86% | Shs Outstand | 157.39M | Perf Week | 2.65% |
| Market Cap | 9.76B | Forward P/E | — | EPS next Y | -6.50 | Insider Trans | -12.08% | Shs Float | 137.07M | Perf Month | 10.67% |
| Enterprise Value | 8.38B | PEG | — | EPS next Q | -2.11 | Short Float | 10.67% | Perf Quarter | 15.88% | ||
| Income | -1.06B | P/S | — | EPS this Y | — | Short Ratio | 7.88 | Perf Half Y | 8.96% | ||
| Sales | 0.00 | P/B | 3.54 | EPS next Y | — | ROA | -33.91% | Short Interest | 14.62M | Perf YTD | 34.44% |
| Book/sh | 17.52 | P/C | 6.57 | EPS next 5Y | — | ROE | -37.57% | 52W High | 90.75 -31.65% | Perf Year | 42.53% |
| Cash/sh | 9.45 | P/FCF | — | EPS past 3/5Y | — | ROIC | -40.55% | 52W Low | 39.87 55.58% | Perf 3Y | 29.28% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 4.04% 6.76% | Perf 5Y | 173.14% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 3.57 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 5.72 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 48.81 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 5.72 | EPS Q/Q | -61.48% | SMA20 | -4.64% | Beta | 1.30 | Target Price | 122.33 |
| Payout | 0.00% | Debt/Eq | 0.04 | Sales Q/Q | — | SMA50 | 0.69% | Rel Volume | 0.82 | Prev Close | 62.61 |
| Employees | 507 | LT Debt/Eq | 0.04 | Earnings | Nov 03 | SMA200 | 8.75% | Avg Volume | 2.10M | Price | 62.03 |
| IPO Date | Jun 12, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 4.16% — | Net Debt/EBITDA | — | Volume | 1,714,259 | Change | -0.93% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-12-26 | Reiterated | Cantor Fitzgerald | Overweight | $120 |
| Oct-05-26 | Reiterated | Guggenheim | Buy | $66 → $125 |
| Oct-05-26 | Reiterated | Needham | Buy | $58 → $122 |
| Nov-19-25 | Reiterated | Leerink Partners | Outperform | $135 → $77 |
| Nov-06-24 | Reiterated | Jefferies | Buy | $129 → $146 |
| Nov-06-24 | Reiterated | Leerink Partners | Outperform | $153 → $135 |
| Sep-10-24 | Reiterated | Mizuho | Outperform | $113 → $163 |
| Sep-04-24 | Reiterated | Bank of America Securities | $101 → $140 | |
| Sep-03-24 | Reiterated | Mizuho Securities | Buy | $113 |
| Sep-03-24 | Reiterated | Leerink Partners | Outperform | $60 → $153 |
Latest News· Times ET
Oct-30-26
Oct-30-2610:55AM
Oct-19-26
Oct-18-26
Oct-18-2602:15AM
Oct-14-26
Oct-14-2610:56AM
Oct-12-26
Oct-12-2602:57AM
02:02AM
Oct-08-26
Oct-08-2607:13AM
Oct-06-26
Oct-06-2610:48PM
04:04PM
10:20AM
08:02AM
Oct-05-26
Oct-05-2610:02PM
04:28PM
01:40PM
12:30PM
Company
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1 | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | -1 | 0 | 0 | 0 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 132 | 129 | 93 | 61 | — | — | — | — | — | |
| Research and Development | 1,033 | 794 | 477 | 332 | — | — | — | — | — | |
| Other Operating Expense | -1 | 1 | 0 | 75 | — | — | — | — | — | |
| Operating Income | -1,165 | -924 | -570 | -468 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 101 | 157 | 106 | 66 | — | — | — | — | — | |
| Net Income Before Taxes | -1,065 | -767 | -464 | -402 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -1,065 | -767 | -464 | -402 | — | — | — | — | — | |
| Net Income From Continuing Operations | -1,065 | -767 | -464 | -402 | — | — | — | — | — | |
| Net Income | -1,065 | -767 | -464 | -402 | — | — | — | — | — | |
| EPS (Recurring) | -7.64 | -5.63 | -3.80 | -4.14 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -7.64 | -5.63 | -3.80 | -4.14 | — | — | — | — | — | |
| EPS (Diluted) | -7.64 | -5.63 | -3.80 | -4.14 | — | — | — | — | — | |
| EBITDA | -1,050 | -742 | -448 | -392 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 144 | 136 | 122 | 97 | — | — | — | — | — | |
| Market Capitalization | 8,932 | 6,275 | 9,987 | 6,092 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Wassil Jim | EVP, Chief Scientific Ofc, COO | Oct 05 '26 | Option Exercise | 5.35 | 18,000 | 96,300 | 163,435 | Oct 07 |
| Cowan Elvia | SVP, Finance & CAO | Oct 05 '26 | Sale | 86.74 | 19,000 | 1,648,060 | 27,860 | Oct 07 |
| Cowan Elvia | SVP, Finance & CAO | Oct 05 '26 | Option Exercise | 25.92 | 19,000 | 492,480 | 46,860 | Oct 07 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO | Oct 05 '26 | Sale | 86.74 | 18,000 | 1,561,320 | 145,435 | Oct 07 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO | Oct 01 '26 | Option Exercise | 5.35 | 2,250 | 12,038 | 147,685 | Oct 02 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO | Oct 01 '26 | Sale | 56.67 | 2,250 | 127,513 | 145,435 | Oct 02 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO | Sep 09 '26 | Sale | 59.52 | 1,334 | 79,401 | 145,435 | Sep 09 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO | Sep 04 '26 | Sale | 61.16 | 1,381 | 84,462 | 152,228 | Sep 09 |
| Wassil Jim | CHIEF OPERATING OFFICER | Sep 01 '26 | Sale | 61.07 | 3,477 | 212,351 | 155,041 | Sep 02 |
| Wassil Jim | CHIEF OPERATING OFFICER | Sep 01 '26 | Option Exercise | 5.35 | 2,250 | 12,038 | 158,518 | Sep 02 |
| Dhaliwal Harpreet S. | Chief Technical Ops Officer | Aug 05 '26 | Option Exercise | 24.79 | 17,000 | 421,430 | 93,756 | Aug 05 |
| Dhaliwal Harpreet S. | Chief Technical Ops Officer | Aug 05 '26 | Sale | 55.00 | 17,000 | 935,068 | 76,756 | Aug 05 |
| Wassil Jim | CHIEF OPERATING OFFICER | Aug 03 '26 | Option Exercise | 5.35 | 2,250 | 12,038 | 159,791 | Aug 05 |
| Wassil Jim | CHIEF OPERATING OFFICER | Aug 03 '26 | Sale | 53.86 | 2,250 | 121,195 | 157,541 | Aug 05 |
| GUGGENHIME ANDREW | PRESIDENT AND CFO | Aug 03 '26 | Option Exercise | 5.35 | 10,000 | 53,500 | 115,176 | Aug 05 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.